Free Trial

Novavax (NVAX) Stock Price, News & Analysis

+0.35 (+2.31%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
12.75 million shs
Average Volume
11.35 million shs
Market Capitalization
$2.18 billion
P/E Ratio
Dividend Yield
Price Target

Novavax MarketRank™ Stock Analysis

Analyst Rating
2.40 Rating Score
12.9% Upside
$17.50 Price Target
Short Interest
32.00% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of Novavax in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$657,637 Sold Last Quarter
Proj. Earnings Growth
From ($0.61) to $0.33 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.70 out of 5 stars

Medical Sector

235th out of 922 stocks

Biological Products, Except Diagnostic Industry

29th out of 153 stocks

NVAX stock logo

About Novavax Stock (NASDAQ:NVAX)

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

NVAX Stock Price History

NVAX Stock News Headlines

5 Meme Stocks With a High Short Interest
No, it's not 2021. But waking up today, you might have been forgiven for thinking so.
5 Meme Stocks With a High Short Interest (NVAX)
Keith Gill, aka RoaringKitty, resurfaces on Twitter, triggering a surge in GameStop and AMC Entertainment shares amid remarkable trading volume.
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report (NVAX)
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report
Arbutus, Novavax See Activist Investor Action
Why Vaccine Stocks Rallied This Week
Novavax (NASDAQ:NVAX) PT Raised to $29.00 at B. Riley
Novavax Unusual Options Activity For May 23
Novavax (NASDAQ:NVAX) Sets New 1-Year High at $15.69
Novavax Sees Unusually Large Options Volume (NASDAQ:NVAX)
3 Biotech Stocks to Buy Now: May 2024
Novavax (NASDAQ:NVAX) Trading Down 8.8%
Is Novavax Stock a Buy?
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$983.71 million
Book Value
($6.18) per share


Free Float
Market Cap
$2.18 billion

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John Joseph Trizzino B.S. (Age 64)
    M.B.A., President & COO
    Comp: $641.22k
  • Mr. James Patrick Kelly C.F.A. (Age 58)
    Executive VP, CFO & Treasurer
    Comp: $644.32k
  • Mr. Stanley Charles Erck (Age 76)
    Comp: $1.09M
  • Mr. John Charles Jacobs M.B.A. (Age 57)
    CEO & Director
  • Mr. Richard P. Crowley (Age 67)
    Executive VP & COO
  • Mr. Troy Morgan Esq. (Age 53)
    J.D., Senior VP & Chief Compliance Officer
  • Mr. Mark Casey
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Erika S. Trahan
    Associate Director of Investor & Public Relations
  • Mr. Ian J. Watkins (Age 61)
    Executive VP & Chief Human Resources Officer
  • Ms. Silvia Taylor M.B.A.
    Executive VP and Chief Corporate Affairs & Advocacy Officer

NVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for Novavax's stock. Their NVAX share price targets range from $10.00 to $29.00. On average, they expect the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2024?

Novavax's stock was trading at $4.80 on January 1st, 2024. Since then, NVAX shares have increased by 222.9% and is now trading at $15.50.
View the best growth stocks for 2024 here

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our NVAX earnings forecast

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by $0.01. The biopharmaceutical company had revenue of $93.90 million for the quarter, compared to analyst estimates of $71.32 million. The business's revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted ($3.41) EPS.

When did Novavax's stock split?

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its FY 2024 earnings guidance on Friday, May, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $400.0 million-$600.0 million, compared to the consensus revenue estimate of $845.5 million.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Who are Novavax's major shareholders?

Novavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.61%), Shah Capital Management (5.78%), TSP Capital Management Group LLC (0.98%), Farallon Capital Management LLC (0.81%), Susquehanna Fundamental Investments LLC (0.22%) and Walleye Trading LLC (0.00%). Insiders that own company stock include David M Mott, Filip Dubovsky, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino and Stanley C Erck.
View institutional ownership trends

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVAX) was last updated on 5/27/2024 by Staff

From Our Partners